Developer docs
API playgroundTry for free, no card

Search company profiles

BennuBio

Full company profile

uuid0000gld

Namestring
BennuBio
Legal namestring
Carlitta N.V.
Websiteurl
bennubio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BennuBio is a privately held life-sciences instrumentation company headquartered in Albuquerque, New Mexico, founded in 2018 with a headcount of 1–10 employees. The company is developing analytical instruments that extend the flow cytometry paradigm to samples of arbitrary particle size and volume — a technical positioning that, if validated, would broaden cytometry beyond its traditional cellular-scale use cases into larger-particle, higher-volume, or non-standard-sample workflows.

The company has assembled a science-led operating team comprising a Founder & Chief Science Officer (James Freyer), a Chief Executive Officer (Steven Graves), a Chief Financial Officer (Steve McKernan), and a Chief Technology Officer (Travis Woods). Capital formation has been the dominant strategic activity to date: a $1.5M seed in September 2018, a $5.0M Series A in April 2020 led by Cowin Venture with co-investment from Cottonwood Technology Fund, Sun Mountain Capital, Tramway Venture Partners, and New Mexico Vintage Fund, followed by small follow-on tranches from New Mexico Angels in 2022 ($45K) and 2023 ($10K), and participation in the BioTools Innovator program in June 2023. No commercial product launch, customer logo, revenue figure, or go-to-market motion is disclosed in the available data, indicating the company remains in an early development or pre-commercial stage.

Note on the input: a substantial block of the aggregated material describes an unrelated online gambling platform (Pinco Casino / Carlitta N.V.) under the BennuBio record, which appears to be a data-attribution error. The company description above is grounded in the firmographic, funding, and leadership data that consistently describe a flow-cytometry instrumentation business.

Short descriptiontext

BennuBio is a privately held Albuquerque-based life-sciences instrumentation company (founded 2018, 1–10 employees) developing flow cytometry-based analyzers capable of handling samples of arbitrary particle size and volume.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAlbuquerque, United States
HQ citystring
Albuquerque
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
flow cytometry instruments, cell analysis systems, life sciences instrumentation, particle size analysis, biotech research tools
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Flow Cytometry Instrumentation
No data
Revenue model3 records
1Online Casino Gaming
TypeTransaction Fee
Description

Platform charges a house edge on casino games including slots, table games, and live dealer games. Revenue generated from player losses on games.

bennubio.com
2Sports Betting
TypeTransaction Fee
Description

Commission earned on sports betting wagers across live and pre-match markets for football, tennis, esports, and cyber sports.

bennubio.com
3Bonus Wagering Requirements
TypeTransaction Fee
Description

Revenue generated when players fail to meet wagering requirements on bonuses (x50 multiplier on welcome bonuses, x50 on freespin wagers, x3 on cashback).

bennubio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details3 tiers
1Welcome Package - Up to 900 AZN + 290 Free Spins
ModelSubscriptionBilling cadenceOne time/ perpetual license
Notes

150% bonus on first deposit up to 900 AZN plus 290 freespin for deposits of 10+ AZN. Wagering requirement: x50. Validity: 30 days for bonus, 7 days for freespin.

bennubio.com
2Weekly Cashback - Up to 20%
ModelUsage-basedBilling cadenceMonthly
Notes

Up to 20% cashback on lost amounts. Wagering requirement: x3. Applied on weekly basis.

bennubio.com
3Tournament Rewards
ModelOtherBilling cadenceMulti-year contract
Notes

Prize pools for tournaments like Supreme Club Cup and others. Terms vary by individual tournament schedule.

bennubio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BennuBio develops flow cytometry-based instruments that analyze biological samples regardless of particle size or sample volume. The technology applies the standard flow cytometry paradigm to a broader range of sample types, enabling research and clinical applications beyond the constraints of conventional flow cytometry systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Minimum deposit as low as 5 AZN
+2 more records
Product overview1 text field

Pinco Casino is an online gambling platform licensed by Curaçao eGaming. The platform offers a unified product combining casino gaming (slots, live dealers, crash games) with sports betting (pre-match and live betting on football, tennis, esports). It includes a mobile Android application and supports local Azerbaijani payment methods (m10, eManat) alongside cryptocurrency. The platform features a loyalty program with Pincoins and various bonuses including welcome packages, freespins, and weekly cashback.

Product and service1 record
1Flow Cytometry Instrument Platform
CategoryLife Sciences Instrumentation
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Curaçao eGaming
Strategic tierCoreTypeOthers
Description

Licensing authority providing international gambling license 8048/JAZ for legal operation. Regulates and monitors gaming activities ensuring compliance with international standards.

bennubio.com
2Evolution Gaming
Strategic tierCoreTypeTechnology or Integration
Description

Live dealer game provider powering real-time casino experiences including roulette, blackjack, and baccarat tables.

bennubio.com
3Pragmatic Play
Strategic tierCoreTypeTechnology or Integration
Description

Slot game provider offering premium titles like Big Bass Bonanza. One of the leading content suppliers for the platform.

bennubio.com
4Nolimit City
Strategic tierCoreTypeTechnology or Integration
Description

Slot game developer providing high-volatility titles like Mental with unique xWays and xNudge mechanics.

bennubio.com
Strategic tierCoreTypeTechnology or Integration
Description

Slot game developer providing Money Train 3 with persistent payer and bonus round features.

Strategic tierCoreTypeTechnology or Integration
Description

Crash game provider powering Aviator with 97% RTP and controlled risk mechanics.

7Carlitta N.V.
Strategic tierCoreTypeOthers
Description

Operating company managing the Pinco Casino platform under Curaçao eGaming license.

bennubio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Local Azerbaijani payment system integrated for deposits and withdrawals with processing times of 15 minutes to 2 hours.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Physical payment terminal network in Azerbaijan enabling cash deposits to user accounts instantly.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Part of Danaher's Life Sciences segment and one of the largest manufacturers of flow cytometry instruments and reagents. Directly comparable as an established flow cytometry hardware competitor with deep clinical and research installed base.

TypeBroad incumbent
Description

BD's cell analysis franchise (including the FACSDuet, FACSChorus, and BD FACSDiscover systems) is a market-leading flow cytometry platform serving research and clinical diagnostics. Comparable as the dominant incumbent in conventional flow cytometry.

TypeBroad incumbent
Description

Markets the Attune NxT flow cytometer and a broad portfolio of flow cytometry antibodies, kits, and instruments. Comparable as a large incumbent covering both flow cytometry hardware and consumables.

TypeDirect peer
Description

Developer of the Aurora and Northern Lights spectral flow cytometers, a newer-generation flow cytometry platform that has gained significant share in immunology and immuno-oncology research. Closest direct comparable as a venture-backed flow cytometry instrument company that displaced incumbents with a differentiated optical architecture.

TypeEmerging player
Description

Diagnostics company using cell mechanical properties and rapid cytometry-based technology (IntelliSep) for sepsis triage. Comparable as a flow cytometry-adjacent tools company applying the paradigm to clinical diagnostic use cases — BennuBio's "any particle size or sample volume" positioning points toward similar adjacent applications.

TypeDirect peer
Description

Specialty manufacturer of high-performance flow cytometry instruments (S1000, SE520) targeting research and biopharma customers. Comparable as a smaller, specialized flow cytometry hardware peer focused on flexibility and configurability.

TypeDirect peer
Description

UK-based specialist in flow cytometry instruments capable of measuring small particles and bacteria — directly aligned with BennuBio's "regardless of particle size" positioning. Comparable as a niche flow cytometry peer targeting applications that conventional cytometers cannot address.

TypeBroad incumbent
Description

Life-science research tools provider with the ZE5 cell analyzer and a broad flow cytometry / droplet digital PCR portfolio. Comparable as an incumbent in cell analysis instrumentation serving research and biopharma workflows.

TypeEmerging player
Description

Specialty lab instrumentation company (cell counters, spectrophotometers, fluorometers) that has scaled from a small startup into a multi-product life-science tools business. Comparable as a small-cap life-science instrumentation peer that has successfully scaled specialized bench-top instruments.

10Sony Biotechnology
TypeBroad incumbent
Description

Provider of the SH800 and MA900 cell sorters and the SA3800 spectral analyzer — competes in flow cytometry cell sorting with proprietary microfluidics/optics. Comparable as a specialty instrumentation competitor that has commercialized novel flow cytometry architectures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BennuBio

Flow Cytometry Instrumentationbennubio.com

BennuBio is a privately held Albuquerque-based life-sciences instrumentation company (founded 2018, 1–10 employees) developing flow cytometry-based analyzers capable of handling samples of arbitrary particle size and volume.

What BennuBio does

BennuBio is a privately held life-sciences instrumentation company headquartered in Albuquerque, New Mexico, founded in 2018 with a headcount of 1–10 employees. The company is developing analytical instruments that extend the flow cytometry paradigm to samples of arbitrary particle size and volume — a technical positioning that, if validated, would broaden cytometry beyond its traditional cellular-scale use cases into larger-particle, higher-volume, or non-standard-sample workflows.

The company has assembled a science-led operating team comprising a Founder & Chief Science Officer (James Freyer), a Chief Executive Officer (Steven Graves), a Chief Financial Officer (Steve McKernan), and a Chief Technology Officer (Travis Woods). Capital formation has been the dominant strategic activity to date: a $1.5M seed in September 2018, a $5.0M Series A in April 2020 led by Cowin Venture with co-investment from Cottonwood Technology Fund, Sun Mountain Capital, Tramway Venture Partners, and New Mexico Vintage Fund, followed by small follow-on tranches from New Mexico Angels in 2022 ($45K) and 2023 ($10K), and participation in the BioTools Innovator program in June 2023. No commercial product launch, customer logo, revenue figure, or go-to-market motion is disclosed in the available data, indicating the company remains in an early development or pre-commercial stage.

Note on the input: a substantial block of the aggregated material describes an unrelated online gambling platform (Pinco Casino / Carlitta N.V.) under the BennuBio record, which appears to be a data-attribution error. The company description above is grounded in the firmographic, funding, and leadership data that consistently describe a flow-cytometry instrumentation business.

BennuBio firmographics

Firmographics
Name
BennuBio
Legal name
Carlitta N.V.
Website
https://bennubio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
BennuBio is a privately held Albuquerque-based life-sciences instrumentation company (founded 2018, 1–10 employees) developing flow cytometry-based analyzers capable of handling samples of arbitrary particle size and volume.
Ownership category
akta.pro rank

BennuBio industry classification

Industry
Product category
Flow Cytometry Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Flow cytometry instruments
  • Cell analysis systems
  • Life sciences instrumentation
  • Particle size analysis
  • Biotech research tools

Where BennuBio is headquartered

Location

Headquarters

HQ city
Albuquerque
HQ country
United States
HQ region
North America

Markets served

BennuBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Online Casino Gaming: Platform charges a house edge on casino games including slots, table games, and live dealer games. Revenue generated from player losses on games.
  2. Sports Betting: Commission earned on sports betting wagers across live and pre-match markets for football, tennis, esports, and cyber sports.
  3. Bonus Wagering Requirements: Revenue generated when players fail to meet wagering requirements on bonuses (x50 multiplier on welcome bonuses, x50 on freespin wagers, x3 on cashback).

Pricing tiers

ModelBillingPrice
SubscriptionOne time/ perpetual licenseWelcome Package - Up to 900 AZN + 290 Free Spins
Usage-basedMonthlyWeekly Cashback - Up to 20%
OtherMulti-year contractTournament Rewards

Distribution channels3 records

Marketing channels4 records

BennuBio product offering

Product offering

Core offering

BennuBio develops flow cytometry-based instruments that analyze biological samples regardless of particle size or sample volume. The technology applies the standard flow cytometry paradigm to a broader range of sample types, enabling research and clinical applications beyond the constraints of conventional flow cytometry systems.

Product overview

Pinco Casino is an online gambling platform licensed by Curaçao eGaming. The platform offers a unified product combining casino gaming (slots, live dealers, crash games) with sports betting (pre-match and live betting on football, tennis, esports). It includes a mobile Android application and supports local Azerbaijani payment methods (m10, eManat) alongside cryptocurrency. The platform features a loyalty program with Pincoins and various bonuses including welcome packages, freespins, and weekly cashback.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flow Cytometry Instrument Platform

Quantifiable outcome

  • Minimum deposit as low as 5 AZN
  • +2 more outcomes

Companies that use BennuBio

Customer profile

Segments3 records

Ideal customer profiles1 record

BennuBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BennuBio partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • Curaçao eGamingcoreOthersLicensing authority providing international gambling license 8048/JAZ for legal operation. Regulates and monitors gaming activities ensuring compliance with international standards.
  • Evolution GamingcoreTechnology or IntegrationLive dealer game provider powering real-time casino experiences including roulette, blackjack, and baccarat tables.
  • Pragmatic PlaycoreTechnology or IntegrationSlot game provider offering premium titles like Big Bass Bonanza. One of the leading content suppliers for the platform.
  • Nolimit CitycoreTechnology or IntegrationSlot game developer providing high-volatility titles like Mental with unique xWays and xNudge mechanics.
  • Relax GamingcoreTechnology or IntegrationSlot game developer providing Money Train 3 with persistent payer and bonus round features.
  • SpribecoreTechnology or IntegrationCrash game provider powering Aviator with 97% RTP and controlled risk mechanics.
  • Carlitta N.V.coreOthersOperating company managing the Pinco Casino platform under Curaçao eGaming license.
  • m10 Payment SystemcoreChannel Partner/ Reseller/ DistributorLocal Azerbaijani payment system integrated for deposits and withdrawals with processing times of 15 minutes to 2 hours.
  • eManat Payment TerminalscoreChannel Partner/ Reseller/ DistributorPhysical payment terminal network in Azerbaijan enabling cash deposits to user accounts instantly.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

BennuBio competitors and assessment

Company assessment

Broad incumbents

  • Beckman Coulter Life Sciences: Part of Danaher's Life Sciences segment and one of the largest manufacturers of flow cytometry instruments and reagents. Directly comparable as an established flow cytometry hardware competitor with deep clinical and research installed base.
  • BD Biosciences: BD's cell analysis franchise (including the FACSDuet, FACSChorus, and BD FACSDiscover systems) is a market-leading flow cytometry platform serving research and clinical diagnostics. Comparable as the dominant incumbent in conventional flow cytometry.
  • Thermo Fisher Scientific (Life Sciences / Cell Analysis): Markets the Attune NxT flow cytometer and a broad portfolio of flow cytometry antibodies, kits, and instruments. Comparable as a large incumbent covering both flow cytometry hardware and consumables.
  • Bio-Rad Laboratories: Life-science research tools provider with the ZE5 cell analyzer and a broad flow cytometry / droplet digital PCR portfolio. Comparable as an incumbent in cell analysis instrumentation serving research and biopharma workflows.
  • Sony Biotechnology: Provider of the SH800 and MA900 cell sorters and the SA3800 spectral analyzer — competes in flow cytometry cell sorting with proprietary microfluidics/optics. Comparable as a specialty instrumentation competitor that has commercialized novel flow cytometry architectures.

Direct peers

  • Cytek Biosciences: Developer of the Aurora and Northern Lights spectral flow cytometers, a newer-generation flow cytometry platform that has gained significant share in immunology and immuno-oncology research. Closest direct comparable as a venture-backed flow cytometry instrument company that displaced incumbents with a differentiated optical architecture.
  • Stratedigm: Specialty manufacturer of high-performance flow cytometry instruments (S1000, SE520) targeting research and biopharma customers. Comparable as a smaller, specialized flow cytometry hardware peer focused on flexibility and configurability.
  • Apogee Flow Systems: UK-based specialist in flow cytometry instruments capable of measuring small particles and bacteria — directly aligned with BennuBio's "regardless of particle size" positioning. Comparable as a niche flow cytometry peer targeting applications that conventional cytometers cannot address.

Emerging players

  • Cytovale: Diagnostics company using cell mechanical properties and rapid cytometry-based technology (IntelliSep) for sepsis triage. Comparable as a flow cytometry-adjacent tools company applying the paradigm to clinical diagnostic use cases — BennuBio's "any particle size or sample volume" positioning points toward similar adjacent applications.
  • DeNovix: Specialty lab instrumentation company (cell counters, spectrophotometers, fluorometers) that has scaled from a small startup into a multi-product life-science tools business. Comparable as a small-cap life-science instrumentation peer that has successfully scaled specialized bench-top instruments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

BennuBio compliance and trust

Trust signal

Compliance1 record

BennuBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BennuBio leadership team

Management profile

Number of profiles

Profiles4 records

BennuBio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BennuBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BennuBio

What does BennuBio do?

BennuBio develops flow cytometry-based instruments that analyze biological samples regardless of particle size or sample volume. The technology applies the standard flow cytometry paradigm to a broader range of sample types, enabling research and clinical applications beyond the constraints of conventional flow cytometry systems.

Is BennuBio a public or private company?

BennuBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was BennuBio founded?

BennuBio was founded in 2018. It employs 1 to 10 people.

Where is BennuBio based?

BennuBio is headquartered in Albuquerque, United States, in the North America region.

How does BennuBio make money?

Three revenue lines are on record. Online Casino Gaming is the primary driver. The others are sports Betting and bonus Wagering Requirements.

Who are BennuBio's main competitors?

Broad incumbents on record are Beckman Coulter Life Sciences, BD Biosciences, Thermo Fisher Scientific (Life Sciences / Cell Analysis), Bio-Rad Laboratories and Sony Biotechnology. Direct peers are Cytek Biosciences, Stratedigm and Apogee Flow Systems. Emerging players are Cytovale and DeNovix.

Does BennuBio have an API?

No public API is recorded for BennuBio.

What industry is BennuBio in?

BennuBio's product category is Flow Cytometry Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsPrecision Cell Systems Makes a Bold Move with BennuBio Acquisition to Tackle 3D Cell CulturePrecision Cell Systems has acquired BennuBio, a life science firm based in New Mexico, integrating the company's Velocyt imaging flow cytometer technology into its portfolio for high-throughput analysis of 3D cell culture models including spheroids and organoids. The deal marks PCS's third acquisition in 2025 alongside S2 Genomics and ORFLO, as the company executes a consolidation strategy in the rapidly expanding 3D cell culture market projected to grow from over $1.7 billion to more than $3.2 billion by 2030. The acquisition also brings BennuBio's primary investor Tramway Ventures into PCS's shareholder base, providing additional financial backing for scaling the technology.PR NewswirePrecision Cell Systems Acquires BennuBio to Enter the 3D Cell Culture MarketPrecision Cell Systems (PCS) announced its acquisition of BennuBio, a New Mexico-based company specializing in high-throughput analysis of 3D multicellular models, to enter the 3D cell culture market. This strategic move expands PCS's capabilities in single-cell analysis and biotechnology applications, aligning with its growth strategy. The 3D cell culture market is expected to grow significantly, surpassing $3.2 billion by 2030.GlobeNewswireBennuBio Welcomes New COOBennuBio announced that Matthew Hess joined as Chief Operations Officer. He brings over 20 years of experience, including roles at Intellicyt and IsoPlexis. The company's Velocyt instrument targets cancer, immunology, and infectious disease research.